



Draft Abridged Prospectus
Dated: April 23, 2026

PRAMODINI MEDICARE LIMITED

CIN: U85110AP2000PLC035231

Registered Office	Corporate Office	Contact Person	Email and Telephone	Website
D. No: - 29-4-54K, CSI Complex, Prakasam Road, Suryaraopet, Vijayawada, Andhra Pradesh, India-520002.	NA	Mr. Rushikesh Vijay Gosavi, Company Secretary & Compliance Officer	Email: investors@pramodinidiagnostic.com Telephone: +91 9985782727	www.pramodinidiagnostics.com

THE PROMOTERS OF OUR COMPANY ARE DR. CHALASANI KULDEEP KUMAR, DR. CHALASANI KAVITHA, MS. CHALASANI DURGA AASHRITHA AND M/S. SRI RAM MEDICARE PRIVATE LIMITED

DETAILS OF OFFER TO PUBLIC, PROMOTER SELLING SHAREHOLDERS

TYPE	FRESH ISSUE	SIZE OF OFFER FOR SALE	TOTAL OFFER SIZE	ELIGIBILITY AND SHARE RESERVATION AMONG QIBs, NIIs AND IIs
Fresh Issue & Offer for Sale	Up to 53,50,800 Equity Shares aggregating up to ₹ [●] Lakhs	Up to 5,00,400 Equity Shares aggregating up to ₹ [●] Lakhs	Up to 58,51,200 Equity Shares aggregating up to ₹ [●] Lakhs	The Offer is being made in Terms of Regulation 229 (2) and 253 (1) and 253 (2) of the SEBI ICDR Regulations 2018 and as amended. For details in relation to share reservation among QIBs, Non-Institutional Bidders and Individual Bidder, see "Offer Structure" beginning on page 362 of the Draft Red Herring Prospectus.

OFS: Offer for Sale

DETAILS OF OFFER FOR SALE, PROMOTER SELLING SHAREHOLDERS AND THEIR WEIGHTED AVERAGE COST OF ACQUISITION

NAME	CATEGORY OF SHAREHOLDER	NO. OF SHARES OFFERED	WACA PER EQUITY SHARE (IN ₹) *
Dr. Chalasani Kuldeep Kumar	Promoter Selling Shareholder	Up to 2,14,400 Equity Shares aggregating up to ₹ [●] Lakhs.	6.99
Dr. Chalasani Kavitha	Promoter Selling Shareholder	Up to 1,43,000 Equity Shares aggregating up to ₹ [●] Lakhs.	6.23
M/S. Sri Ram Medicare Private Limited	Promoter Selling Shareholder	Up to 1,43,000 Equity Shares aggregating up to ₹ [●] Lakhs.	4.25

* As certified by Statutory Auditor of our Company, by way of their certificate dated April 23, 2026.

RISKS IN RELATION TO THE FIRST OFFER

This being the first public offer of our Company, there has been no formal market for the Equity Shares. The face value of Equity Shares is ₹10/- each. The Floor Price, Cap Price and Offer Price (determined by our Company and the promoter selling shareholders in consultation with the Book Running Lead Manager, in accordance with the SEBI ICDR Regulations), and on the basis of the assessment of market demand for the Equity Shares by way of Book Building Process as stated in "Basis for Offer Price" beginning on page 103 should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active and/or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and bidders should not invest any funds in the offer unless they can afford to take the risk of losing their investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the offer. For taking an investment decision, Bidders must rely on their own examination of our company and the offer, including the risks involved. The equity shares in the offer have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 23 of the Draft Red Herring Prospectus.

COMPANY'S, PROMOTERS AND PROMOTER SELLING SHAREHOLDER'S ABSOLUTE RESPONSIBILITY

Our company, having made all reasonable inquiries, accepts responsibility for and confirms that the Draft Red Herring Prospectus contains all information with regard to our company and the offer, which is material in the context of the offer, that the information contained in the Draft Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes the Draft Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect. The promoter selling shareholder, accepts responsibility for and confirms only the statements expressly and specifically made by him in the Draft Red Herring Prospectus to the extent of information specifically pertaining to them and their respective portion of the offered Shares and assumes responsibility that such statements are true and correct in all material respects and not misleading in any material respect. The Promoter Selling Shareholder assume no responsibility, as a Promoter Selling Shareholder, for any other statement in the Draft Red Herring Prospectus, including, inter alia, any of the statements made by or relating to our company or our company's business or any other person(s).

LISTING

The equity shares offered through the Draft Red Herring Prospectus are proposed to be listed on Emerge Platform of NSE ("NSE EMERGE"). Our company has received "In-Principle" approval from the NSE Emerge for using its name in the offer document for the listing of the Equity Shares, pursuant to letter dated [●]. For the purpose of the offer, the designated stock exchange shall be NSE.

BOOK RUNNING LEAD MANAGER TO THE OFFER

Name and Logo	Contact Person	Email & Telephone
 CAPITAL ADVISORS PVT. LTD. Smart Horizon Capital Advisors Private Limited	Mr. Parth Shah	E-mail: director@shcapl.com Telephone: 022-28706822

REGISTRAR TO THE OFFER

Name and Logo	Contact Person	Email & Telephone
 Purva Share Registry (India) Private Limited	Ms. Deepali Gaonkar	E-mail: newissue@purvashare.com Telephone: 022 4961 4132

BID/OFFER PROGRAMME

ANCHOR INVESTOR BID/ OFFER PERIOD: [●] *	BID/OFFER OPENS ON: [●] *	BID/OFFER CLOSES ON: [●] **
--	---------------------------	-----------------------------

*Our Company and the Promoter Selling Shareholders in consultation with the BRLM may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/ Offer Period shall be one Working Day prior to the Bid/Offer Opening Date.

**Our Company and the Promoter Selling Shareholders may, in consultation with the BRLM, consider closing the Bid/Offer Period for QIBs one Working Day prior to the Bid/ Offer Closing Date in accordance with the SEBI ICDR Regulations.

The UPI mandate end time and date shall be at 5:00 p.m. on Bid/Offer Closing Day.

IN THE NATURE OF DRAFT ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE DRAFT RED HERRING PROSPECTUS



(Please scan this QR code to Draft Red Herring Prospectus and Draft Abridged Prospectus)

The following is a general summary of certain disclosures in the Draft Red Herring Prospectus and the terms of the Offer and is not exhaustive, nor does it purport to contain a summary of all the disclosures in the Draft Red Herring Prospectus or all details relevant to prospective investors. This summary should be read in conjunction with, and is qualified in its entirety by, the more detailed information appearing elsewhere in the Draft Red Herring Prospectus, which is available at the website of Securities and Exchange Board of India ("SEBI") at www.sebi.gov.in, at the websites of the Emerge Platform of NSE at www.nseindia.com, at the website of the Company at www.pramodiniagnostics.com and the website of the Book Running Lead Managers at www.shcapl.com.

References below are to the page numbers of the Draft Red Herring Prospectus dated April 23, 2026. Unless otherwise specified all capitalized terms used herein and not specifically defined bear the same meaning as ascribed to them in the Draft Red Herring Prospectus.

1. Summary of the Primary Business

Our Company is a diagnostic service provider in India. We provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. The services offered at each location vary based on the scope agreed under the respective MOUs. We provide healthcare services for core testing, patients diagnosis, disease prevention and monitoring of various health conditions.

a) The business overview including products/services offered by the Company: Our diagnostic services include a comprehensive range of offerings: (i) "Radiology" which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X-ray, Ultrasound with colour doppler, Mammography, Dexa Scan and Intervention Radiology, (ii) "Clinical Laboratory" which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) "Nuclear Medicine" which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy. We also provide teleradiology services through our registered office situated at Vijayawada which functions on a 24x7 basis throughout the year.

b) Description of industries served and typical customer/clients of the Company: Our business operates across four key models namely 1. Public Private Partnership (with government hospitals and government teaching hospitals) 2. Private Private Partnership (with private sector hospitals) 3. Strategic Partnership with PSUs (Public Sector Undertakings) Government of India and 4. Private Centres (standalone centre).

c) Segment reporting details and their revenue contribution for the reporting periods: Our Company is engaged in the business of providing diagnostic service and providing a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges. For further details, please see chapter titled "Our Business-Revenue Break-Up" on page 138.

d) Key Geographies Served: For the period ended on December 31, 2025, our Company generated total revenue from operations of ₹4,445.29 lakhs. The majority of the revenue was contributed by Andhra Pradesh (60.82%) and Karnataka (20.09%), followed by Uttar Pradesh (10.56%) and West Bengal (8.53%). The remaining revenue was generated from several other states across India, each contributing a relatively smaller share, reflecting the Company's geographically diversified customer base. For further details, please see chapter titled "Our Business-Revenue Break-Up" on page 137.

e) Revenue concentration among top 5 customers: The contribution of the top five customers in Revenue is Rs. 2,860.92 lakhs (64.36 %) for the period ended on December 31, 2025, Rs. 2,878.02 lakhs (75.27 %) for FY 2024-25, Rs. 2,849.16 lakhs (80.87%) for FY 2023-24, and Rs. 2,316.73 lakhs (75.76 %) for FY 2022-23.

f) Key manufacturing or other facilities: We have 3 (three) establishments comprising our Registered office cum diagnostic and Imaging Centre, Branch office cum Diagnostic and Imaging Centre and Lab Processing Unit in Vijayawada to support business operations and patient servicing.

g) Business strengths and strategies:

Our business strengths are:

- Establishing a Strategic presence across various states of India
- Strengthening Our Network with Diversified Models
- Technical Capability with robust IT Infrastructure
- Dedicated Management Team with Significant Industry Experience
- Track record of revenue and financial performance
- Diverse Customer cum Patient Base

Our business strategies are:

- Expanding geographic footprint across the India
- Increase in capacities at our existing diagnostic facilities
- Expand our business and geographical footprint through opportunistic acquisitions
- Continue to improve profitability and efficiency
- Enhancing our brand image

For further details, please refer to the chapter titled "Our Business" beginning on page 133 of the Draft Red Herring Prospectus.

2. Summary of the Industry

- The Indian healthcare sector, valued at Rs. 9,42,590 crore (US\$ 110 billion) in 2016 and Rs. 31,87,668 crore (US\$ 372 billion) in 2023, is projected to reach Rs. 54,67,022 crore (US\$ 638 billion) by 2025, growing at a robust 17.5-22.5% CAGR, driven by innovation across hospitals, pharmaceuticals, and diagnostics.
- The telemedicine market is expected to reach Rs. 47,130 crore (US\$ 5.4 billion) by 2025, driven by increased demand for remote healthcare solutions and advancements in technology.
- India's hospital market was valued at US\$ 126 billion in FY24, projected to grow at a CAGR of 8.0% from FY24 to FY32, reaching an estimated value of US\$ 193.59 billion by FY32.

For further details, please refer to the chapter titled “*Industry Overview*” beginning on page 116 of the Draft Red Herring Prospectus.

3. Promoters of our Company

Sr. No.	Name of the Promoter	Individual/Corporate	Experience & Educational Qualification/ Corporate Information
1.	Dr. Chalasani Kuldeep Kumar	Individual	He is the Promoter, Chairman and Managing Director of our Company. He completed his degree of Bachelor of Medicine & Bachelor of Surgery (Faculty of Medicine) from Nagpur University in April 2002. Thereafter, he completed his degree of Doctor of Medicine (Radio-Diagnosis) from Rajiv Gandhi University of Health Sciences, Karnataka in March 2006. In his previous stint, he served as Chief Resident at Grant Medical College & Sir J.J. Group of Hospitals Mumbai. He has also worked as an Associate Professor at Dr Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation in April 2015. He holds life membership of Indian Radiological & Imaging Association through the Andhra Pradesh state chapter and is also a life member of the Indian Medical Association. He is having overall work experience of more than 20 years in the field of Medicine, Surgery and Radio-Diagnosis. He has been associated with our Company since 2015 and has experience of more than 10 years in our Company.
2.	Dr. Chalasani Kavitha	Individual	She is the Promoter and Non-Executive Director of our Company. She completed her Bachelor of Medicine and Bachelor of Surgery (MBBS) from Kasturba Medical College, Manipal, under Manipal Academy of Higher Education in August 1999. She also completed her Master of Surgery (MS) in Obstetrics and Gynecology from Kasturba Medical College, Manipal, under Manipal Academy of Higher Education in September 2003. She has also obtained the Diplomate of the National Board (DNB) in Obstetrics and Gynaecology from the National Board of Examinations, New Delhi in 2005. Further, she obtained a fellowship in Gynecological Endoscopy from Rajiv Gandhi University of Health Science, Karnataka in March 2008. Further, she was awarded Dr. P. Amini Memorial Award for being the best outgoing student in M.D. (Obstetrics & Gynecology) in the examination held in 2003. She has been associated with our Company since the year 2015 and has experience of more than 20 years in the field of Obstetrics and Gynecology.
3.	Ms. Chalasani Durga Aashritha	Individual	She is the Promoter and Non-Executive Director of our Company. She is currently pursuing her Third Professional MBBS (Part II) course at Dr. Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation. She has been associated with our Company since September 2025.
4.	M/s. Sri Ram Medicare Private Limited	Corporate	M/s. Sri Ram Medicare Private Limited was incorporated on March 15, 2012 as a private limited company registered under the Companies Act, 1956 via certificate of incorporation dated March 15, 2012 issued by the Registrar of Companies, Andhra Pradesh vide CIN U85100AP2012PTC079774 and is not listed on any stock exchange.

For further details, please refer to the chapter titled “*Our Promoters and Promoter Group*” beginning on page 191 of the Draft Red Herring Prospectus.

4. Objects of the Offer

The Offer comprises a Fresh Issue of up to 53,50,800 equity shares of face value ₹ 10, aggregating up to ₹ [●] lakhs by our Company and an Offer for Sale of up to 5,00,400 equity shares of face value ₹ 10, aggregating to ₹ [●] lakhs by the Promoter Selling Shareholders.

Our Company proposes to utilize the Net Proceeds from the Fresh Issue towards funding the following objects:

Sr. No.	Particulars of Object	Description
1.	Funding of capital expenditure for purchase of Medical Equipments towards Existing and Proposed Diagnostic Centres; (₹4,514.85 lakhs)	Our Company intends to purchase and install medical equipments across three of our existing diagnostic centres. At Hubli (Karnataka), we propose to expand our capacity by installing additional equipments. At Manjeri (Kerala), where operations are yet to commence, we intend to install the required medical equipments. Further, at Vijayawada (Andhra Pradesh), out of three proposed equipments only one equipment will be replaced with existing equipment. Also, we intend to leverage our operational experience and further expand our operations in proposed centre in Bangalore in the state of Karnataka.
2.	General corporate purposes and unidentified inorganic acquisition;	We will evaluate inorganic growth opportunities, keeping in line with our strategy to grow and develop our market share or to add service offerings.

For further details, please refer to the chapter titled “*Objects of the Offer*” beginning on page 94 of the Draft Red Herring Prospectus.

5. Pre and post offer shareholding of Promoter(s), members of the Promoter Group and top 10 shareholders

Sr. No.	Particulars	Pre-Offer as at the date of the Draft Red Herring Prospectus		Post-Offer shareholding as at Allotment*			
		Number of Equity Shares of face value ₹10 each	Percentage of total pre-Offer paid up Equity Share capital	At the lower end of the Price Band (₹ ●)		At the upper end of the Price Band (₹ ●)	
				Number of Equity Shares of face value ₹10 each	Percentage of total post -Offer paid up Equity Share capital	Number of Equity Shares of face value ₹10 each	Percentage of total post -Offer paid up Equity Share capital
Promoters							
1	Dr. Chalasani Kuldeep Kumar	80,87,586	48.44%	[●]	[●]	[●]	[●]
2	Dr. Chalasani Kavitha	16,34,737	9.79%	[●]	[●]	[●]	[●]
3	M/s Sri Ram Medicare Private Limited	45,87,154	27.48%	[●]	[●]	[●]	[●]
	Total (A)	1,43,09,477	85.71%	[●]	[●]	[●]	[●]
Promoter Group							
	NA	NA	NA	NA	NA	NA	NA

	Total (B)	-	-	-	-	-	-
Additional top 10 shareholders							
1.	Mr. Yash Hitesh Patel	8,34,756	5.00%	[●]	[●]	[●]	[●]
2.	Ms. Yashvi Hitesh Patel	7,92,831	4.75%	[●]	[●]	[●]	[●]
3.	Ms. Sumita Mishra	3,33,892	2.00%	[●]	[●]	[●]	[●]
4.	Mr. Sadineni Raghu Teja	2,14,214	1.28%	[●]	[●]	[●]	[●]
5.	Mr. Siva Rama Krishna Prasad Attluri	83,863	0.50%	[●]	[●]	[●]	[●]
6.	Ms. Karri Mani Kumari	41,925	0.25%	[●]	[●]	[●]	[●]
7.	Mr. Swapnil Sudhakar Rao Topale	41,925	0.25%	[●]	[●]	[●]	[●]
8.	Mr. Jay Ashok Shah	20,956	0.13%	[●]	[●]	[●]	[●]
9.	Ms. Priti Surya Prakash Mishra	20,956	0.13%	[●]	[●]	[●]	[●]
10.	NA	NA	NA	NA	NA	NA	NA
	Total (C)⁽²⁾	23,85,318	14.29%	[●]	[●]	[●]	[●]
	Total (A+B+C)	1,66,94,795	100.00%	[●]	[●]	[●]	[●]

Notes:

1) Based on the Offer Price of ₹ [●] and subject to finalization of the basis of allotment.

2) As on the date of the Draft Red Herring Prospectus, we have total 12 (Shareholders), out of which 9 are Public Shareholders.

For detailed information on the “*Capital Structure*”, please refer on page 80 of the Draft Red Herring Prospectus.

6. Summary of Restated Financial Information

The following details are derived from the Restated Consolidated Financial Information as at for the period ended on December 31, 2025 and for the Financial Years ended March 31, 2025, March 31, 2024 and March 31, 2023:

(₹ in Lakhs)

Particulars	For the period ended December 31, 2025	For Fiscal Year		
		March 31, 2025	March 31, 2024	March 31, 2023
Share Capital	128.42	128.42	128.42	128.42
Net Worth#	4,388.10	3,131.15	2,126.92	1,526.55
Revenue from operations\$	4,445.29	3,823.77	3,522.95	3,058.14
EBITDA	2,233.75	2,096.61	1,553.47	1,467.16
Profit after Tax	1,256.95	1,004.24	576.48	428.32
Basic Earnings Per Share@	7.87	6.92	4.59	4.53
Diluted Earnings Per Share@	7.87	6.92	4.59	4.53
Return on Equity / Net Worth	27.83%	30.81%	25.56%	25.91%
*Net Asset Value per Equity Shares (Post Bonus)	27.05	19.52	13.51	10.03
^Total Borrowings (as per Restated)	1,103.14	1,081.42	1,196.24	2,139.41
Cash flow from operating activities	2,898.37	2,212.13	985.36	705.86
Cash flow from investing activities	-2,966.85	-1,065.58	-138.13	-374.15
Cash flow from financing activities	-51.82	-639.1	-1,081.01	-113.58

Notes:

Net Worth = Restated Equity Share Capital plus Restated Reserves & Surplus

\$ Revenue = Restated Revenue from operations

@ Earnings per share (Basic & diluted) = Restated profit after tax for the period divided by Restated weighted average number of Equity Shares outstanding during the period

*Net Asset Value per Equity Share = Restated Net worth divided by Restated weighted average number of Equity Shares outstanding during the period

^Total Borrowings = Restated Long-Term Borrowings Plus Restated Short-Term Borrowings

For details, see “*Restated Consolidated Financial Information*”, “*Other Financial Information*” and “*Management’s Discussion and Analysis of Financial Conditions and Results of Operations*” on pages 200, 301 and 309, respectively.

7. Summary of Key Performance Indicators

Details of our KPIs as of and for the period ended on December 31, 2025 and Fiscal 2025, Fiscal 2024 and Fiscal 2023:

(₹ in Lakhs, otherwise mentioned)

Particulars	For the Period ended December 31, 2025	For the year ended on		
		March 31, 2025	March 31, 2024	March 31, 2023
Revenue From operations (1)	4,445.29	3,823.77	3,522.95	3,058.14
EBITDA (2)	2,233.75	2,096.61	1,553.47	1,467.16
EBITDA Margin (%) (3)	50.25%	54.83%	44.10%	47.98%
Profit/(loss) after tax for the year (4)	1,256.95	1,004.24	576.48	428.32

PAT Margin (%) (5)	28.28%	26.26%	16.36%	14.01%
Return on Equity (RoE) (%) (6)	32.33%	36.42%	29.50%	31.45%
Return on Capital Employed (%) (7)	32.34%	39.15%	33.93%	25.64%
Net Capital Turnover Ratio (in Times) (8)	42.65	6.38	8.73	38.19
Debt to Equity Ratio (in Times) (9)	0.24	0.33	0.53	1.29
Current Ratio (in times) (10)	0.84	1.58	1.28	1.17

**As certified by Peer review Auditors, by way of their certificate dated April 22, 2026.*

Notes:

⁽¹⁾ Revenue from operations means revenue from sales and other operating revenues

⁽²⁾ EBITDA is calculated as Profit before tax + Depreciation + Finance Cost - Other Income

⁽³⁾ 'EBITDA Margin' is calculated as EBITDA divided by Revenue from Operations

⁽⁴⁾ PAT is calculated as Profit before tax – Tax Expenses

⁽⁵⁾ 'PAT Margin' is calculated as PAT for the year divided by revenue from operations

⁽⁶⁾ Return on Equity is the ratio of Profit after Tax and Average Shareholder Equity

⁽⁷⁾ Return on Capital Employed is calculated as follows: Profit before tax + Finance Costs (EBIT) divided by (Tangible Net Worth + Total Debt + Deferred Tax Liabilities)

⁽⁸⁾ Net Capital Turnover Ratio is calculated as revenue from operations divided by average working capital.

⁽⁹⁾ Debt to Equity ratio is calculated as Long Term Debt + Short Term Debt divided by equity

⁽¹⁰⁾ Current Ratio is calculated by dividing Current Assets by Current Liabilities

For further details, please refer to the chapter titled "Basis for Offer Price" beginning on page 103 of the Draft Red Herring Prospectus.

8. Risk Factors

The following are the top 10 internal risk factors as disclosed in the DRHP:

1. A significant portion of our revenue from operations is derived from MOUs with government authorities under Public Private Partnership (PPP) arrangements. Any non-renewal, modification, or termination of such MOUs, or delays or failures in realizing payments from government authorities, may materially and adversely affect our business, financial condition and results of operations.
2. Concentrated emphasis on radiology services also exposes us to substantial risks that could adversely impact our operations, financial performance, and long-term growth prospects.
3. We derive substantial portion of our revenue from the state of Andhra Pradesh and any loss of business in such regions could have an adverse effect on our business, results of operations and financial condition.
4. We are majorly dependent on certain key customers cum patients for a substantial portion of our revenues. Loss of relationship with any of these customers cum patients may have a material adverse effect on our profitability and results of operations.
5. We derive a significant portion of our revenue from government authorities (B2G). Any reduction in revenue from them or delays in payments by government authorities, may adversely affect our business, financial condition and results of operations.
6. Failure to establish and comply with appropriate quality standards when performing diagnostics services could result in litigation and liability for us and could materially and adversely affect its reputation and results of operations.
7. We rely on our information technology systems in providing our diagnostic services and managing our operations, and any disruption to such systems or networks could adversely affect our business operations, reputation and financial performance.
8. Any inadequacy in packaging, collection of, or failure or delay in the delivery of, specimens to our diagnostic centres could compromise or destroy the integrity of such specimens, which could adversely affect our business, results of operations and financial condition.
9. The prices that we can charge for our diagnostic services are dependent on recommended or mandatory fees fixed under the terms of the MOUs entered into with public sector enterprises, state governments and some of private medical establishments.
10. We have not yet placed orders in relation to the capital expenditure requirements of the Company towards purchase of certain medical equipments for our existing and proposed diagnostic centres. In the event of any delay in placing the orders, or if the vendors are unable to provide the equipments in a timely manner, or at all, the same may result in time and cost overruns.

For further details, please refer to the chapter titled "Risk Factor" beginning on page 23 of the Draft Red Herring Prospectus. Investors are advised to read the risk factors carefully before making an investment decision in the Offer.

9. The details of weighted average cost of acquisition of shares for Promoters (including our Promoter Selling Shareholders)

The weighted average cost of acquisition of Equity Shares of our Promoters (including our Promoter Selling Shareholders), are as follows:

Types of transactions	Weighted average cost of acquisition per Equity Share (in ₹)	Cap Price is 'X' times the weighted average cost of acquisition *	Range of acquisition price: per Equity Share: lowest price – highest price (in ₹) *
Weighted average cost of acquisition of primary issuances as per paragraph (a) above	NA	NA	NA
Weighted average cost of acquisition for secondary transactions as per paragraph (b) above	34.95	[•]	[•]
Weighted average cost of acquisition for past 5 primary issuances / secondary transactions, as per paragraph (c) above	NA	NA	NA

** To be included upon finalization of the Price Band and will be updated at the Red Herring Prospectus stage.*

As certified by our Statutory Auditors, by way of their certificate dated April 23, 2026.

For further details, please refer to the chapter titled "Basis for Offer Price" beginning on page 103 of the Draft Red Herring Prospectus.

10. Board of Directors and Key Managerial Personnel

S. No.	Name	Designation
Board of Directors		
1.	Dr. Chalasani Kuldeep Kumar	Chairman and Managing Director
2.	Dr. Chalasani Kavitha	Non-Executive Director
3.	Ms. Chalasani Durga Aashritha	Non-Executive Director
4.	Mr. A Ajay Kumar	Non-Executive Independent Director
5.	Dr. Eshwar Chandra Nandury	Non-Executive Independent Director
6.	Mr. Manas Dash	Non-Executive Independent Director
Key Managerial Personnel		
7.	Mr. Rushikesh Vijay Gosavi	Company Secretary and Compliance Officer
8.	Mr. Rajkamal Kona	Chief Financial Officer (CFO)

For further details, please refer to the chapter titled “*Our Management*” beginning on page 175 of the Draft Red Herring Prospectus

11. Auditor Qualifications

The Statutory Auditors of our Company have not expressed any qualification, reservation, adverse remark, matter of emphasis, or other observation on our financial statements for the periods covered in the Draft Red Herring Prospectus.

12. Summary table of Outstanding Litigations

Name of Entity	Criminal Proceedings	Tax Proceedings	Disciplinary actions by the SEBI or Stock Exchanges against our Promoters	Material Civil Litigations	Aggregate amount involved (Rs. In Lakhs)
By the Company	Nil	Nil	Nil	Nil	Nil
Against the Company	Nil	7	Nil	1	0.26
By our Directors	Nil	Nil	Nil	Nil	Nil
Against the Directors	Nil	Nil	Nil	Nil	Nil
By Promoters	Nil	Nil	Nil	Nil	Nil
Against Promoters	Nil	13	Nil	1	1.72
By our KMPs & SMPs	Nil	Nil	Nil	Nil	Nil
Against the KMPs & SMPs	Nil	Nil	Nil	Nil	Nil
By the Group Companies / Entities	Nil	Nil	Nil	Nil	Nil
Against the Group Companies / Entities	Nil	10	Nil	1	9.91

**Our Promoters are also the director of the Company. Hence litigations against them have not been included under the heading of director to avoid repetition.*

For further details, please refer to the chapter titled “*Outstanding Litigation and Material Developments*” beginning on page 328 of the Draft Red Herring Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended (the “Securities Act”) or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be offered and sold outside the United States in offshore transactions in reliance on Regulations under the Securities Act and in compliance with the applicable laws of the jurisdiction where such offers and sales occur. There will be no public offering of the Equity Shares in the United States.